Pathophysiology of endotoxic shock, F. Forfori et al.
Fluids in shock, M. Cecconi et al.
It is time for improved fluid stewardship, M. LNG Malbrain, T.W. Rice, M. Mythen
Vasoactive medication and RCTs, J. Gutteling & A.R.J. Girbes
Advances in source control in patients with sepsis and septic shock, J.J. De Waele & I. Martin-Loeches
Organ cross-talk in shock and critical illness, J.R. Prowle
POCUS and SHOCK, A. Wong & J. Wilkinson

PLUS

Xenon limits brain damage following cardiac arrest, M. Maze & T. Laitio
What’s new in sepsis in children? E. Esteban et al.
Optimising sleep in the ICU, M.C. Reade & D. Liu
Cancer patients in the ICU, I. Prieto del Portillo et al.
What should we stop doing in the ICU? F.G. Zampieri
Caring for very old patients in the ICU, H. Flaatten
The sepsis box, bag and trolley, C. Hancock & A. Hermon
Humanizing the ICU experience with enhanced communication, A. Rocher
Implementing ECCO₂R and vv-ECMO in non-academic centres, K. Kogelmann
Improving access to safe anaesthesia, J. Mellin-Olsen
Xenon, a chemically inert but biologically active monatomic gas, has been applied in patients for anaesthesia/sedation, and most recently in the critical care of patients with acute ongoing neurological damage.

Following preclinical evidence that xenon has ameliorative activity in several pathobiologic pathways that are involved in central nervous system injury, xenon was shown to be effective at improving both morphology and function in a series of models of hypoxic/ischaemic injury that simulate stroke (both haemorrhagic and ischaemic), neonatal asphyxia, as well as the ischaemic-reperfusion injury that occurs in the post-cardiac arrest syndrome (PCAS).

These promising findings prompted a Phase 2 RCT that revealed that a 24-hour xenon administration during targeted temperature management (TTM) resulted in significantly less brain damage than TTM alone in PCAS. A pivotal, multicentre, Phase 3 RCT is now underway to establish the efficacy (primary endpoint is survival with good functional outcome) and safety of xenon in PCAS.

Stroke
Ischaemia is the cause in ~85% of adult stroke victims. Dirnagl and colleagues (2014; 1999) have offered important insights into the potentially-modifiable processes that obtain in ischaemic stroke (Figure 1). Sudden interruption of perfusion to discrete brain regions heralds a phase of excitotoxicity due to ischaemia-induced depolarisation of glutamatergic neurons causing release of the excitatory neurotransmitter, glutamate. Activation by glutamate of its cognate receptor subtypes results in a massive influx of calcium cations that produces neuronal death through necrosis. In the subacute phase of ischaemic stroke, cell death occurs through apoptotic processes. In the later phases brain damage can be produced by inflammatory processes initiated by engagement of the innate immune response (Dirnagl et al. 1999).

The haemorrhagic form of stroke is mainly caused by subarachnoid and intracerebral haemorrhage. The former type accounts for 5% to 10% of all strokes and is mostly attributed to rupture of an aneurysm. Apart from the decreased perfusion and ischaemia in the territory of the ruptured blood vessel engendering excitotoxicity, additional pathophysiologic processes supervene due to the collection of extravascular blood (cytotoxic effect) (Budohoski et al. 2014). Because of perturbed cerebrospinal fluid hydrodynamics, the intracranial pressure may rise resulting in failure to adequately perfuse other brain regions. Together with vasospasm, disruption of the blood-brain barrier and the superintervention of inflammation, delayed cerebral ischaemia exacerbates the patient’s neurologic deficits. However, the contribution of vasospasm to delayed cerebral injury following subarachnoid haemorrhage (SAH) has been challenged (Budohoski et al. 2014). It is notable that SAH remains an unmet treatment challenge,
and novel interventions, including xenon, are worthy of consideration.

Cardiac arrest
Cardiac arrest is the classical example of ischaemic-reperfusion injury in which the absence of any perfusion to the brain provokes excitotoxicity (Neumar et al. 2008). Successful resuscitation and restoration of spontaneous circulation causes a new pathophysiological process characterised by apoptosis and neuroinflammation.

Traumatic brain injury
Traumatic brain injury encompasses heterogeneous conditions from diverse types of trauma of varying severity; as such, different pathophysiological pathways may be involved and major international efforts are more precisely characterising the evolution of injury (International Initiative for Traumatic Brain Injury Research [IntTBI - intbirc.nih.gov]; Transforming Research and Clinical Knowledge in Traumatic Brain Injury [TRACKTBI - tracktbi.ucsf.edu]). From these efforts, much has been learned about genetic factors that modulate the host-response to injury by proteins such as apolipoprotein E (Lawrence et al. 2015), mitochondrial DNA haplotype (Bulstrode et al. 2014) and brain-derived neurotrophic factor (Failla et al. 2016). Physiologic monitoring has yielded information on dysregulation of intracranial pressure, autoregulation of brain perfusion, brain oxygenation and metabolism, inflammation and cortical electrical activity. Macroscopically several types of Lesions can be distinguished including shearing of white matter tracts, contusions, haematomas and oedema. A secondary wave of damage occurs hours to days after the traumatic event that is characterised by excitotoxicity, free radical generation, mitochondrial dysfunction, mass effect, ischaemia and inflammatory responses (Maas et al. 2008). Especially in the setting of repetitive trauma, processes are initiated that result in long-term consequences such as dementia, Parkinsonism, and epilepsy.

Neuroprotective properties of xenon
Xenon is an antagonist of the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor (Franks et al. 1998), a pivotal mediator of the excitotoxicity that is ubiquitously present in acute ongoing neurological injury from a variety of causes. NMDA-receptor antagonists are neuroprotective in vitro and in vivo brain injury models (Choi et al. 1988). Interventions, such as ketamine, that produce NMDA antagonism through ion pore blockade, result in the development of “Olney’s lesions” with psychotomimetic effects (Olney et al. 1991). Xenon produces its NMDA antagonism by competing with glycine at the co-activation site (Dickinson et al. 2007); hence xenon does not induce the Olney’s lesions or behavioural changes that characterise the direct ion pore blockers. In fact, xenon ameliorates the injury produced by other NMDA-receptor antagonists (Nagata et al. 2001). Xenon protects against injury induced by NMDA, glutamate or oxygen-glucose deprivation (Wilhelm et al. 2002). Other complementary neuroprotective properties of xenon include interruption of apoptosis (Ma et al. 2005), activation of species of ion channels that result in membrane hyperpolarisation (Bantel et al. 2010; Gruss et al. 2004) and a generalised cytoprotective action initiated by upregulation of hypoxia-inducible factor-1α (HIF-1α) and its downstream protective effectors (namely, erythropoietin) within the brain under normoxic conditions (Ma et al. 2009).

The neuroprotective properties of xenon have been corroborated in preclinical models of hypoxic ischemic encephalopathy (Wilhelm et al. 2002; Ma et al. 2006; Dingley 2006; Rajakumaraswamy et al. 2006; Dingley et al. 2008; Cattano et al. 2008; Valleggi et al. 2008; Luo et al. 2008; Bantel et al. 2009,) stroke (Homi et al. 2003; David et al. 2003; Limatola et al. 2010; David et al. 2010; Sheng et al. 2012), traumatic brain injury (Coburn et al. 2008; Harris et al. 2013; Campos-Pires et al. 2015, Campos-Pires et al. 2018) anaesthetic-induced developmental neurotoxicity (Ma et al. 2007; Cattano et al. 2008a; Shu et al. 2010; Cattano et al. 2011; Sabir et al. 2013), and cardiac arrest (Schmidt et al. 2005; Fries et al. 2008; Fries et al. 2012). Preclinical studies have also shown that xenon and targeted temperature management (TTM; currently, the standard of care for post-cardiac arrest syndrome) can be combined to protect in an additive or super-additive (synergistic) manner. Data, published in eight peer-reviewed manuscripts from four different laboratories involving four preclinical injury models, demonstrate that xenon’s neuroprotective action is most

---

**Figure 1.** Pathobiologic changes following ischaemic stroke

In this schematic diagram the major damage-inducing changes following ischaemic stroke are depicted over time following the acute ictus. Also depicted are the mechanisms that can protect against the damage at the various epochs during stroke evolution (Modified from Dirnagl et al. 2014). Reproduced with permission.
Effective when body temperature is reduced (Ma et al. 2005; Martin et al. 2007; Hobbs et al. 2008; Thoresen et al. 2009; Chakkarapani et al. 2010; Faulkner et al. 2011; Fries et al. 2012; Sabir et al. 2014). Unlike other neuroprotective strategies, including a different NMDA-receptor antagonist (gavestinel), xenon alone exhibits this enhanced efficacy when temperature is reduced.

**Clinical evidence for the neuroprotective properties of xenon**

The Xe-hypotheca trial (NCT 00879892 - clinicaltrials.gov/ct2/show/NCT00879892) studied the Effect of Inhaled Xenon on Cerebral White Matter Damage in Comatose Survivors following an Out-of-Hospital Cardiac Arrest (Laitio et al. 2016). The trial, which was undertaken at the medical centres of Turku and Helsinki Universities in Finland, enrolled 110 successfully resuscitated patients with post-cardiac arrest syndrome. The trial compared xenon (up to 50% by inhalation) plus the standard of care (SOC) versus SOC alone for the primary endpoint of white matter brain damage (global fractional anisotropy [GFA] derived from a diffusion tensor imaging sequence); both arms were inclusive of TTM administered for 24 hrs. Assessment of the GFA revealed significantly (P=0.006) reduced brain damage in the subjects randomised to receive xenon. There was 41.7% less damage to white matter tracts (from the approximately 115,000 voxels assessed in each patient) in the Xenon + SOC vs SOC alone group. The relative damage to the major white matter tracts in the two groups is depicted (Figure 2).

**Figure 2.** Differences in white matter tract injury between standard of care (SOC) vs Xenon + SOC groups in patients with post-cardiac arrest syndrome

Sagittal plane sections of the overlaid white matter tracts (inferior to superior) are illustrated in which red indicates tracts with statistically less damage (higher fractional anisotropy) in the xenon + SOC group vs. SOC alone group. In green are tracts that are no different between the two groups either because no injury occurred or because xenon did not reverse injury in these tracts. In no tracts was injury significantly less severe in the control group. (Modified from Laitio et al. 2016). Reproduced with permission.

**Subarachnoid haemorrhage remains an unmet treatment challenge and novel interventions, including xenon, are worthy of consideration**

Xe-HYPOTHECA was not powered to detect differences in functional endpoints; reduction in 6-month mortality rate - 27% in the xenon group and 35% in the SOC group (adjusted hazard ratio, 0.49 [95% CI, 0.23-1.01]) - did not achieve statistical significance (P = 0.053). The degree of white matter injury was the strongest predictor of mortality at 6 months.

**Clinical evidence for the myocardial protective properties of xenon**

A predefined secondary objective of the XeHypotheCA Trial was to assess the effect of inhaled xenon on myocardial ischemic damage. Troponin-T (TnT) levels were measured at hospital admission, and at 24h, 48h and 72h post-cardiac arrest (Arola et al. 2017). The baseline characteristics did not differ significantly between the groups. Results are tabulated (Table 1). After adjustments for age, gender, study site, primary coronary percutaneous intervention (PCI), and norepinephrine dose, the mean standard deviation post-arrival incremental change of the ln-transformed troponin-T at 72 hours was 0.79 (1.54) in the xenon group and 1.56 (1.38) in the control group (adjusted mean difference, -0.66 [95% CI, -1.16 — -0.16], P=0.01). The decline of TnT from the peak value at 24h to 72h was significantly greater in the xenon group than in the control group (p =0.0008). The effect of xenon on the change in the troponin-T values did not differ in patients with or without PCI or in those with a diagnosis of ST-elevation myocardial infarction (group by PCI or STEMI interaction effect, P=0.86 and P=0.71, respectively). In comparison with hypothermia alone, inhaled xenon combined with hypothermia resulted in less severe myocardial injury as demonstrated by the significantly reduced release of troponin-T.

**Future applications of xenon for critical care**

Apart from the potential use of xenon for postoperative sedation (Bedi et al. 2003), and for selected intraoperative settings, e.g., for neurosurgical procedures (Rylova and Maze 2018) it is unlikely that xenon will be considered for routine use in perioperative settings both because of the availability of cheaper alternatives and because of the
need for recirculating systems to minimise consumption of xenon.

Nonetheless, in critical care settings where there is an unmet medical need, e.g., Post-Cardiac Arrest Syndrome, xenon’s cytoprotective effects may be further appreciated for its physico-chemical properties that result in a near instantaneous onset of action together with a low potential for toxicity through its chemical non-reactivity. A pivotal 1436-patient Phase 3 Trial (Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of Out-of-Hospital Cardiac Arrest (XePOHCAS - NCT03176186 - clinicaltrials.gov/ct2/show/NCT03176186)) has been launched to determine the efficacy and safety of 24h inhalation of xenon to improve survival with good functional outcome in successfully resuscitated (ROSC ≤ 30 min), but still comatose, victims of a witnessed cardiac arrest.

### Production and availability of xenon

Xenon is an extremely rare element present in the atmosphere at approximately 88 parts/billion. Xenon is produced by a process of cryogenic distillation in which air is fractionated into its primary components by cooling at high pressure until it liquefies; the different components are then separated according to physical characteristics, including boiling points and density, within specialized cryogenic columns. The process consumes large amounts of energy and those fractions which are found in low concentrations (i.e., xenon) require multiple distillations, and are therefore extremely expensive to produce to medical grade purity of 99.999%. The estimated total supply of xenon is thought to be 14 million litres, of which 50% could theoretically be delivered in medical grade. Approximately 50L of xenon is required for a 24-hour intervention; under these conditions approximately 140,000 patients could be treated annually.

### Conclusions

Xenon, the noble elemental gas, may benefit the critically ill patient that has ongoing acute neurological injury because it reduces the activity in several of the pathobiologic pathways that obtain in these conditions. A definitive, pivotal, multicentre, trial to establish xenon’s safety and efficacy in the setting of post-cardiac arrest syndrome is now being prosecuted. If successful, the next challenge will be to increase the production of medical grade xenon through the retrofitting of oxygen-purification plants. Further refinements in the recirculation and recycling of xenon can further improve the availability of this scarce resource.

### Conflict of interest

Mervyn Maze is a co-founder, and shareholder of equity in NPXe Ltd, a company that seeks to commercialise neuroprotective applications of xenon. TL is a member of the Trial Executive Committee for XePOHCAS, a phase 3 RCT designed to test the efficacy and safety of patients with post-cardiac arrest syndrome. The XePOHCAS trial is sponsored by NeuroproteXeon.

### Abbreviations

- PCAS: post-cardiac arrest syndrome
- ROSC: return of spontaneous circulation
- SOC: standard of care
- TnT: Troponin-T
- TTM: targeted temperature management

### References

For full references, please email editorial@icumanagement.org or visit https://iii.hm/o26

---

**Table 1. Troponin-T change from baseline to 72 h after OHCA**

<table>
<thead>
<tr>
<th></th>
<th>Xenon Group (n = 54)</th>
<th>Control Group (n = 54)</th>
<th>Mean Difference (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Absolute values, µg/l</td>
<td></td>
<td>Unadjusted</td>
<td>Adjusted*</td>
</tr>
<tr>
<td></td>
<td>ln ΔTnT 24 h</td>
<td>1.40 ± 1.39</td>
<td>-0.26 [-0.79 to 0.27]</td>
<td>0.33</td>
</tr>
<tr>
<td></td>
<td>ln ΔTnT 48 h</td>
<td>1.00 ± 1.37</td>
<td>-0.28 [-0.80 to 0.25]</td>
<td>0.29</td>
</tr>
<tr>
<td></td>
<td>ln ΔTnT 72 h</td>
<td>0.79 ± 1.54</td>
<td>-0.76 [-1.33 to -0.20]</td>
<td>0.009</td>
</tr>
</tbody>
</table>

- Δ change from the baseline CI confidence interval ln natural logarithm OHCA out-of-hospital cardiac arrest TnT troponin-T
- Note 1: Values are median (interquartile range) or mean ± standard deviation, unless otherwise indicated.
- Note 2: Natural logarithmic transformation for troponin-T values was used in the statistical analysis due to skewness of the data.